Mendelspod Podcast

20:08

How Is the Brexit Impacting Genomics? with Clare...

Mendelspod Podcast ·

2016/07/12

Today's guests have been separately on the program recently. And we've asked them, both Brits, to come back on for a discussion of the Brexit. Clare Turnbull is Clinical Lead for the 100K Genomes Project Cancer Program at Genomics England. Hadyn Parry is the CEO at Oxitec, a company based in Oxford which is already selling their genetically engineered mosquitos into Brazil to deal with viral diseases like Zika and Dengue Fever. This is a public episode. If you'd like to discuss this with other

en

19:52

It’s Not Really Bulls and Bears: John Carroll on His...

Mendelspod Podcast ·

2016/07/07

John Carroll has been the editor-in-chief at Fierce Biotech for thirteen years. Now he's moved to a new gig. Two weeks ago, he and a former colleague launched a new and independent life science media site, Endpoints. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

23:42

June 2016 with Nathan and Laura: GMO Labeling,...

Mendelspod Podcast ·

2016/07/05

Today's show was recorded July 1st, the first day that Vermont’s GMO labeling law went into effect. Just how big a win was this for the anti-GMO crowd, we ask our two commentators, Nathan Pearson and Laura Hercher. They have a surprisingly optimistic take, suggesting that the GMO labeling could become a positive marketing tool. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

35:31

Know Then Thyself: Kari Stefansson, deCODE genetics

Mendelspod Podcast ·

2016/06/30

Kari Stefansson is a name well known in the field of human genetics. His founding of deCODE genetics in his native Iceland in 1996 took our field into a new frontier with the unique opportunity to work with not only a homogenous population but also to integrate with a large centralized healthcare database. It also surfaced a huge ethical debate about genomic privacy. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

19:12

Sequenom Patent Loss a Threat to Personalized...

Mendelspod Podcast ·

2016/06/29

It’s a non-decision with big implications. On Monday, the Supreme Court turned down an appeal by Sequenom in their patent case with Ariosa. The rebuff by the highest court kills Sequenom’s prenatal screening test patent for good. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

18:51

Bringing Home Some Diagnostics Gold: Brad Gray,...

Mendelspod Podcast ·

2016/06/24

You hear it everywhere. And it’s getting old. That "diagnostics is a tough slog.” That it’s the “redheaded stepchild of healthcare.”And today’s guest doesn’t disappoint, repeating both these phrases. But Brad Gray and NanoString can claim some big “slogging" success. They’re coming out on top in diagnostics through some clever business strategy built on a solid platform. Made CEO at just 33 years of age, Brad has taken NanoString public and overseen a successful expansion from the research

en

21:56

Mukherjee Mess-up, the Secret Harvard Meeting, and...

Mendelspod Podcast ·

2016/06/06

Today we look back on the genomics headlines over the past month (and a few days). To do this we’re joined by our regular commentators, Nathan Pearson and Laura Hercher.First we take on the science journalism kerfuffle of the year. When Pulitzer Prize winning author, Siddhartha Mukerjee, got epigenetics wrong in his New Yorker piece, scientists came out en masse to denounce it. Nathan reassures us that scientists aren’t afraid of writers. This is a public episode. If you'd like to discuss this

en

23:35

When Do We Move to Population Based Cancer Screening...

Mendelspod Podcast ·

2016/05/24

Last year when we were promised a soon-to-be-on-the-market, pan cancer, genetic based screening test, many of us were taken aback at the hubris. Not only does the science have a ways to go, there are deep ethical conflicts to work through. However, cancer screening based on a patient’s genetics is already being done in certain niche areas. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

25:29

The Solid Future of Liquid Biopsies with Michael...

Mendelspod Podcast ·

2016/05/19

There’s been lots in the news this past year about liquid biopsies—those non-invasive tests which locate biomarkers in a vial of blood. Much of that press (perhaps too much) has been about using these blood tests for cancer screening: predictive tests that could be available to consumers some time in the future. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

25:05

Genomics Is Oversubscribed, Says Creator of BLAST

Mendelspod Podcast ·

2016/05/12

One of the original Celera team that worked on the Human Genome Project, Gene Myers is now setting up the new Center for Systems Biology at the Max Planck Institute of Molecular Cell Biology and Genetics.However, unlike many others such centers, the main focus of this institute will not be genomics. Rather Myers is going for microscopy.“Genomics is only about 20% of it,” he says in today’s interview from his office in Dresden, Germany This is a public episode. If you'd like to discuss this with

en

28:32

With 10K Genomes Sequenced, Genomics England in High...

Mendelspod Podcast ·

2016/05/05

We’ve heard on the program over the past few years that genomic medicine will probably take off first in a country with a centralized health service. And when the U.K. announced their 100K Genomes Project at the end of 2012 with the creation of Genomics England in 2013, it was certainly a bold visionary move to do just that—to put the entire country on a progressive path toward precision medicine for all.So with 10K genomes sequenced, how is the project going? This is a public episode. If you'd

en

22:08

April 2016 with Nathan and Laura: Big Money, More...

Mendelspod Podcast ·

2016/05/02

This month we saw Big Money being infused into genomics and other life science research projects. There’s no question that science is big business, but do we see improved healthcare as a result?Was the NIH too hasty in it’s ban on gene editing of human embryos?Superheroes are lurking among us everywhere . . . or so the mainstream media would have us believe in their take on a new study from the Icahn School of Medicine. This is a public episode. If you'd like to discuss this with other subscribers

en

33:05

A Sneak Peek into the Future of Clinical Genomics...

Mendelspod Podcast ·

2016/04/28

We hear from some that soon each baby's genome will be sequenced at birth. This vast amount of genomic information will be stored in a person's medical record for life and be referenced for personalized healthcare, be it for a diagnostic, a prognostic, or a prediction. But others say that it is still way too early to be generating so much information on each person when we know so little about the genome. This camp argues that we should deal with patients on a case by case basis using a more

en

25:52

Preprints and the Future of Science Publishing with...

Mendelspod Podcast ·

2016/04/11

A renewed effort has been underway by leading biologists this year to persuade their colleagues to preprint. This is the posting of a paper to an open access server before peer review and publication. The proponents argue that preprinting will be good for science because discoveries will be made available sooner. The peer review process can take several months, and by preprinting, a biologist doesn’t have to wait to get their work out there and begin interacting with the community. This is a

en

27:21

Flipping Drug Development Upside Down: Niven Narain,...

Mendelspod Podcast ·

2016/04/06

The promise of rational drug design has driven pharma companies for years. The history of the industry has been one of trial and error, or “guess and check”, as scientists often say. Companies have screened thousands and thousands of compounds looking for one that might work—the proverbial needle in the haystack. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

21:31

March 2016 with Nathan and Laura: Genomic Jenga and...

Mendelspod Podcast ·

2016/04/01

Which company offers the gold standard of sequencing? Nathan starts us out with a metaphor to compare linked reads with real long reads. Then it’s on to this month’s “knockout paper” that moves us yet further from a deterministic view of genetics. Or is this genomic Jenga part of the “proper design of the Creator”? Laura links a new Indiana law banning abortion due to chromosomal abnormalities such as Down Syndrome to a larger effort by the anti-abortion lobby to go after all genetic testing.

en

30:00

Medicine and the Limits of Science with Michel Accad, MD

Mendelspod Podcast ·

2016/03/30

Are drug prices really too high? If so, how do we bring them down? Is precision medicine and the use of molecular profiles really making a difference in healthcare today?These are questions that regularly haunt our industry and the journalists who cover it. But there will be no answers until we face the grand question of all, what today's guest calls the most nagging question in medicine: What is health?Today we begin a new series focused on just this question. This is a public episode. If you'd

en

36:11

How Good are Linked Reads? Serge Saxonov, 10X Genomics

Mendelspod Podcast ·

2016/03/15

When 10X Genomics launched their GemCode sequencing instrument at last year’s AGBT conference, what they offered seemed too good to be true. 10X was promising researchers a machine that could generate long reads using Illumina’s short read technology at a price lower than what PacBio could offer with their “real” long read instruments. A year earlier, Illumina had announced they were buying Moleculo, a company that promised to offer long read data out of the short reads. But good data with the

en

26:44

A Home Run on the First Hit: PacBio’s Jonas Korlach

Mendelspod Podcast ·

2016/03/08

Jonas Korlach is a natural storyteller—a rare trait in a scientist who is more comfortable presenting data than talking of himself. Jonas is the co-inventor of PacBio’s SMRT (single molecule, real time) sequencing, and we wanted to hear from him directly how it all got started, and also when the team realized that they had something big with long reads and close to 100X coverage. How many of us can boast of hitting it out of the park on our first try? This is a public episode. If you'd like to

en

30:43

Digital Pathology at Scale: Epic Sciences Takes CTC...

Mendelspod Podcast ·

2016/03/03

It’s the beginning of the age of liquid biopsies, when less invasive, regular blood draws will provide more information than the occasional solid tissue biopsy. Companies that offer tests based on circulating tumor cells or cell free DNA in the blood are popping up like genome interpretation companies were a few years ago. As our understanding of biology at the molecular level advances--particularly in the field of cancer research--the more this practical and focused approach for teasing out the

en

All Episodes

Similar Podcasts

Mendelspod Podcast

Theral Timpson

DMCN Journal

John Wiley & Sons Ltd

汪诘：科学有故事（主打）

科学有故事

天方烨谈

基因频道

Homesteading and Permaculture by Paul Wheaton

paul wheaton